Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Paclitaxel Plus Ramucirumab and Tislelizumab as Switch Maintenance Versus Continuation of Chemotherapy and Tislelizumab in Patients With Advanced HER2-negative and PD-L1 Positive Gastroesophageal Adenocarcinoma: the ARMANI-2/ENGIC08 Trial by GONO

NCT07763171 is registered in ClinicalTrials.gov with Gruppo Oncologico del Nord-Ovest as lead sponsor.

NCT NCT07763171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07763171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Paclitaxel Plus Ramucirumab and Tislelizumab as Switch Maintenance Versus Continuation of Chemotherapy and Tislelizumab in Patients With Advanced HER2-negative and PD-L1 Positive Gastroesophageal Adenocarcinoma: the ARMANI-2/ENGIC08 Trial by GONO
Lead sponsor
Gruppo Oncologico del Nord-Ovest
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 30, 2031
Enrollment
244 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal adenocarcinoma